Lord, Abbett & Co
LEGN icon

Lord, Abbett & Co’s Legend Biotech LEGN Stock Holding History

Lord, Abbett & Co’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,385
Closed -$204K – 570
2023
Q4 		$204K Sell
3,385
-57,526
-94% -$3.65M ﹤0.01% 510
2023
Q3 		$4.09M Sell
60,911
-502,798
-89% -$34.9M 0.02% 487
2023
Q2 		$38.9M Buy
563,709
+507,281
+899% +$33.1M 0.13% 221
2023
Q1 		$2.72M Sell
56,428
-341,328
-86% -$16.7M 0.01% 507
2022
Q4 		$19.9M Buy
397,756
+11,562
+3% +$560K 0.07% 351
2022
Q3 		$15.8M Sell
386,194
-371,985
-49% -$17.5M 0.06% 353
2022
Q2 		$41.7M Buy
+758,179
New +$32M 0.15% 196

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Lord, Abbett & Co's LEGN Position: Q1 2024 in Review

Lord, Abbett & Co sold out of Legend Biotech (LEGN) in Q1 2024, closing a stake of 3,385 shares — an estimated $204K sold.

Lord, Abbett & Co first reported a position in LEGN in Q2 2022 and held it in 7 quarters. The position peaked at $41.7M in Q2 2022. 192 funds tracked by Wall St. Rank hold LEGN as of Q1 2024.

  • Lord, Abbett & Co reported no remaining Legend Biotech position as of Q1 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 3,385 Legend Biotech shares in Q1 2024, an estimated $204K.
  • Lord, Abbett & Co first reported a position in Legend Biotech in Q2 2022 and held it in 7 quarters.
  • Lord, Abbett & Co's Legend Biotech position peaked at $41.7M in Q2 2022.
  • 192 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2024.

Based on Lord, Abbett & Co's 13F filing for Q1 2024, filed 9 May 2024.